A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer (NCT07513311)

🧪 Interventions in This Study

• RESTORE (BEHAVIORAL)
• Enhanced Usual Care (BEHAVIORAL)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Massachusetts General Hospital — Boston, Massachusetts

📞 Contact the Study Coordinator

Phone: (617) 726-6500

Email: kepost@mgh.harvard.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Triple Negative Breast Cancer (TNBC)

• OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer — Elizabeth, New Jersey
• A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs) — Syracuse, New York
• PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer — Houston, Texas
• Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer — Grand Rapids, Michigan

Explore by condition: All Triple Negative Breast Cancer (TNBC) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.